As of 2018, the FDA has approved an oncology drug treatment called Vitrakvi that treats patients with cancers that have biomarkers (specific genetic features). Instead of targeting the location of where the tumor originated, Vitrakvi targets common biomarkers in various types of tumors, making it a "tissue agnostic" cancer drug (FDA, 2018). The drug is intended to treat patients with solid tumors that have NTRK gene fusion (neurotrophic receptor tyrosine kinase) without a mutation or are metastatic. The good news of the drug is that it is not cancer-specific as it must use biomarkers to guide drug development to target the disease. New data supports a strong overall response rate of the drug at 78% (BioSpace, 2020). The drug has also shown long-term effectiveness as it has sustained long-term efficacy in a number of TRK (tropomyosin receptor kinase) fusion-positive cancers (PharmaTimes, 2020).